The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data fro...

by Pincelli, Carlo, Henninger, Eric, Casset-Semanaz, Florence
Published 2006

Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15

by Kappos, Ludwig, Kuhle, Jens, Multanen, Juha, Kremenchutzky, Marcelo, Verdun di Cantogno, Elisabetta, Cornelisse, Peter, Lehr, Lorenz, Casset-Semanaz, Florence, Issard, Delphine, Uitdehaag, Bernard M J
Published 2015

Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study

by Freedman, Mark S., De Stefano, Nicola, Barkhof, Frederik, Polman, Chris H., Comi, Giancarlo, Uitdehaag, Bernard M. J., Casset-Semanaz, Florence, Hennessy, Brian, Lehr, Lorenz, Stubinski, Bettina, Jack, Dominic L., Kappos, Ludwig
Published 2014

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes

by De Stefano, Nicola, Comi, Giancarlo, Kappos, Ludwig, Freedman, Mark S, Polman, Chris H, Uitdehaag, Bernard M J, Hennessy, Brian, Casset-Semanaz, Florence, Lehr, Lorenz, Stubinski, Bettina, Jack, Dominic L, Barkhof, Frederik
Published 2014